PTO/SE/ORA (08-00)
Please type a plus sign (+) inside this box 
U.S. Parent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		Complete if Known	RECEI	/FD
Substitute for form 1449A/PTO	Application Number	10/618,977		
INFORMATION DISCUSSIONE	Filing Date	July 14, 2003	CENTRAL FAX	CENTER
INFORMATION DISCLOSURE	First Named Inventor	Brian Bates, et al.	OCT 2-4	2006
STATEMENT BY APPLICANT	Group Art Unit	3738	001 24	2000
(use as many sheets as necessary)	Examiner Name	Thomas Sweet		
Sheet 1 of 4	Attorney Docket Number	PA-5335-RFB (8627/742)		

U.S. PATENT DOCUMENTS

		U.S. Patent	Document		Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Cita No. 1	Number	Kind Code <sup>2</sup> (If knawn)	Name of Patentee or Applicant of Cited Document	Clied Document MM-DD-YYYY	
71JS/	1	4,101,984		MacGregor	07/25/1978	
	2	4,305,926		Everse et al.	12/15/1981	
	3	4,343,788		Mustacich et al.	08/10/1982	
	4	4,476,590		Scales et al.	10/16/1984	
_	6	4,479,795		Mustacich et al.	10/30/1984	
	6	4,502,158		Woodroof et al.	03/05/1985	
	7	4,677,143		Laurin et al.	06/30/1987	
	8	4,769,013		Lorenz et al.	09/06/1988	
	9	4,793,825		Benjamin et al.	12/27/1988	
	10	4,872,867		Joh	10/10/1989	
	11	4,879,135		Greco et al.	11/07/1989	
	12	4,886,062		Wiktor	12/12/1989	
	13	4,909,799		Thulesius et al.	03/20/1990	
	14	4,917,686		Bayston et al.	04/17/1990	
	15	4,925,668		Khan et al.	05/15/1990	
	16	4,950,258		Luther et al.	08/21/1990	
_	17	4,994,047		Walker et al.	02/19/1991	
	18	5,004,461		Wilson	04/02/1991	
	19	5,019,096		Fox, Jr. et al.	05/28/1991	
-	20	5,019,393		Ito et al.	05/28/1991	
+	21	5,019,601		Allen	05/28/1991	
	22	5,053,048	-	Pinchuk	10/01/1991	
-1	23	5,069,166		Fischell et al.	10/22/1991	
$\mathcal{W}$	24	5,067,491		Taylor, II et al	11/26/1991	
_ <del>-</del>	25	5,098,977		Frautschi et al.	03/24/1992	
/TJS/	26	5,102,402		Dror et al.	04/07/1992	
EXAMIN SIGNAT		/Thoma	s J Sweet	(04/11/2007) DATE CONSID	ERED	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not circular is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique charion designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japaness patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>4</sup> Applicant is to place a check mark here if English language Translation is attached.

	Complete If Known		
Substitute for form 1449A/PTO	Application Number	10/618,977	
INFORMATION DISCLOSURE	Filing Date	July 14, 2003	
	First Named Inventor	Brian Bates, et al.	
STATEMENT BY APPLICANT	Group Art Unit	3738	
(use as many sheets as necessary)	Examiner Name	Thomas Sweet	
Sheet 2 of #4	Attorney Docket Number	PA-5335-RFB (8627/742)	

U.S. PATENT DOCUMENTS

		U.S. Patent	Document		Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials*	Citte No.	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Occurrent Mit4-DD-YYYY	Passages or Relevant Figures Appear
/TJS/	27	5,108,424		Hoffman, Jr. et al.	04/28/1992	
	28	5,112,457		Marchant	05/12/1992	
	29	5,135,516		Sahatilen et al.	08/04/1992	
	30	5,163,952		Froix	11/17/1892	
	31	5,165,952		Solomon et al.	11/24/1992	
	32	5,171,217		March et al.	12/15/1992	
	33	5,182,317		Winters et al.	01/26/1993	
	34	5,197,977		Hoffman, Jr. et al.	03/30/1993	
	35	5,217,493		Raad ot al.	06/08/1993	
<u> </u>	38	5.222,971		Willard et al.	06/29/1993	
	37	5,229,172		Cahalan et al.	07/20/1993	
	38	5,244,654		Narayanan	09/14/1993	
	39	5,282,823		Schwartz et al.	02/01/1994	
$\neg$	40	5,298,255		Sawarnoto et al.	03/29/1994	
	41	5,304,121		Sahatian	04/19/1994	
	42	5,314,688		Kauffman et al.	05/24/1894	
	43	5,342,348	f	Kaplan	08/30/1994	
	44	5,344,411		Domb et al.	09/06/1994	
	45	5,344,444		Glastra	09/06/1994	
	46	5,345,933		Peterson et al.	09/13/1994	
$\neg$	47	5,348,873		Matsuda et al.	09/20/1994	
	48	5,356,433	<del></del>	Rowland et al.	10/18/1994	
$\neg \vdash$	49	5,380,299		Fearnot et al.	01/10/1995	
	50	5,383,927		De Golcoechea et al.	01/24/1995	
_	51	5,383,928		Scott et al.	01/24/1995	
	52	5,419,760		Narciso, Jr.	05/30/1995	
	53	5,443,458		Eury	08/22/1995	
	54	5,447,724		Helmus et al.	09/05/1995	
7/7	55	5,449,382		Dayton	09/12/1995	
Ψ-	56	5,454,888		Burrell et al.	10/03/1995	
/TJS/	57	5,455,040		Marchant	10/03/1995	

EXAMINER	DATE CONSIDERED
SIGNATURE /Thomas J Sweet/ (04/11/2007)	

<sup>\*</sup>BNAM DIER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw time through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the useds of the individual case. Any comments on the amount of time you are required to complete this form about be seat to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique ciution designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>6</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the scrial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicent is to place a check mark here if English language Translation is attached.

## PAGE 9110: RCVD AT 10/24/2006 3:36:55 PHI [Eastern Daylight Time] 'SVR:USPTO-EFXRF-3/19' DHIS:2738300 'CSID:8123309049' DURATION (mm-55)-35-34

	Complete If Known		
Substitute for form 1449A/PTO	Application Number	10/618,977	
INFORMATION DISCLOSURE	Filing Date	July 14, 2003	
	First Named Inventor	Brian Bates, et al.	
STATEMENT BY APPLICANT	Group Art Unit	3738	
(use as many sheets as necessary)	Examiner Name	Thomas Sweet	
Sheet 3 of 74	Attorney Docket Number	PA-5336-RFB (8627/742)	

U.S. PATENT DOCUMENTS

		U.S. Patent	Document		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Cite Initials, No.		Number	Kind Code 2 (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
11351	58	5,456,663		Lemeison	10/10/1995		
	59	5,457,113		Cullinan et al.	10/10/1995		
	60	5,464,450		Buscemi et al.	11/07/1995		
	61	5,464,650		Berg et al.	11/07/1995		
	62	5,500,013		Buscemi et al.	03/19/1996		
	63	5,510,330		Martin et al.	04/23/1996		
	84	5,531,716		Luzio et al.	07/02/1996		
	65	5,534,288		Gruskin et al.	07/09/1996		
-	66	5,554,181		Das	09/10/1996		
	67	5,587,495	- i	Modak et al.	10/22/1998		
_	68	5,569,463		Helmus et al.	10/29/1996		
	69	5,578,075		Dayton	11/26/1996		
	70	5,605,896		Eury et al.	02/25/1997		
	71	5,607,463		Schwartz et al.	03/04/1997		
	72	5,607,475		Cahalan et al.	03/04/1997		
	73	5,609,629		Feamot et al.	03/11/1997		
	74	5,624,411		·Tuch	04/29/1997		
	75	5,629,008		Lee	05/13/1997		
	76	5,649,977		Campbell	07/22/1997		
	77	5,679,400		Tuch	10/21/1997	• • •	
	78	5,681,846		Trissel	10/28/1997		
	79	5,697,967		Dinh et al.	12/16/1997		
	80	5,716,981		Hunter et al.	02/10/1998		
	81	5,733,327		Igaki et al.	03/31/1998		
	82	5,762,638		Shikani et al.	06/09/1998		
	83	5,770,198		Coller et al.	06/23/1998		
	84	5,772,640		Modak et al.	06/30/1998		
	85	5,820,607		Tcholakian et al.	10/13/1998		
\ <u>\</u>	86	5,824,049		Regheb et al.	10/20/1998		
	87	5,837,008		Sorg et al.	11/17/1998		
/TJS/_	88	5,853,745		Daroulche	12/29/1998		

EXAMINER SIGNATURE	/Thomas J Sweet/ (04/11/2007)	DATE CONSIDERED

<sup>\*\*</sup>SYAM NER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Parent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique cluston designation number. <sup>2</sup> See structed Kinds of U.S. Parent Documents. <sup>3</sup> Erner Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese parent documents, the indication of the year of the reign of the Emperor must precede the tertial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>4</sup> Applicant is to place a check mark here if English language Translation is attached.

PAGE 10/10 • RCVD AT 10/24/2006 3:38:55 PM [Eastern Daylight Time] • SVR:USPTO-EFXRF-3/19 • DMS:2738300 • CSID:81233909049 • DURATION (mm-s-3):03-34

Substitute for form 1448A/PTO	Complete if Known			
SUBSUILLE IDEFORM 1448APTO	Application Number	10/618,977	RECEI	VEn
INFORMATION DISCLOSURE	Filing Date	July 14, 2003	CENTRAL FA	CENTER
STATEMENT BY APPLICANT	First Named Inventor	Brian Bates, et al.		CENTEH
SINIEMENI BI APPLICANI	Group Art Unit	3738	OCT 24	2006
(use as many sheets as necessary)	Examiner Name	Thomas Sweet	<del></del>	2000
Sheet 4 of \$4	Attorney Docket Number	PA-5335-RFB (8627/742)		

PATENT	

		U.S. Patent Do	ument			Pages, Columns, Lines	
Examiner Cite No. 1		Number	nd Code <sup>3</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
/1JS/	89	5,873,904		Ragheb et al.	02/23/1999		
	90	6,902,283		Darouiche et al.	05/11/1999		
	91	5,886,026		Hunter et. al.	03/23/1999		
	92	6,096,070		Ragheb et al.	08/01/2000	· · · · · · · · · · · · · · · · · · ·	
	93	6,171,232	81	Papadreou et al.	01/09/2001		
	94	6,240,616	81	Yan	06/05/2001		
	95	6,273,908	B1	Ndondo-Lay	08/14/2001		
	96	6,273,913	B1	Wright et al.	08/14/2001		
	97	6,299,604	B1	Ragheb et al.	10/09/2001		
	98	6,306,166	81	Barry et al.	10/23/2001		
	99	6,335,029	B1	Kamath et al.	01/01/2002		
	100	6,599,275	B1	Fischer, Jr.	07/29/2003		
	101	6,730,064	B2	Ragheb et al.	05/04/2004	· · · · · · · · · · · · · · · · · · ·	
	102	6,774,278	B1	Ragheb et al.	08/10/2004		
	103	6,918,927	B2	Bates et al.	07/19/2005		
	104	2003/0028243	A1	Bates et al.	02/06/2003		
	105	2003/0028244	A1	Bates et al.	02/06/2003		
	106	2003/0036794	A1	Ragheb et al.	02/20/2003	······································	
	107	2004/0243225	A1	Ragheb et al.	12/02/2004	•	
	108	2004/0068241	A1	Fischer, Jr.	04/08/2004		
V	109	2004/0073284	A1	Bates et al.	04/15/2004		
	110	2005/0042295	A1	Hunter et al.	02/24/2005	<del></del>	
/TJS/	111	2005/0123605	A1	Hunter et al.	06/09/2005		

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Citte No. 1	Office 3	Code <sup>6</sup>	Name of Patentes or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Peges, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	γ.

EXAMINER	Thomas 1 C at 1 (04/44/2007)	DATE CONSIDERED
SIGNATURE	/Thomas J Sweet/ (04/11/2007)	
0.0.010112		L

<sup>\*</sup>BXAMINES: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique ciexion designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-lotter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the raign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>4</sup> Applicant is to place a check mark here if English language Translation is stucked.

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box 

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

_				Complete if Known		
S	Substitute for form 1	449A/PTO	Application Number	10/618,977		
INFO	MATION DI	SCLOSURE	Filing Date	July 14, 2003		
			First Named Inventor	Brian Bates, et al.		
SIAI	CIVIEN I BY	APPLICANT	Group Art Unit	1762		
(us	e as many sheets a	s necessary)	Examiner Name	Thomas Sweet		
Sheet	1 (	of 2	Attorney Docket Number	PA-5335-RFB (8627/742)		

## **U.S. PATENT DOCUMENTS**

	Cite No.	U.S. Patent Doc	ument		Date of Dublication of	Pages, Columns, Lines,
Examiner Initials*			nd Code <sup>2</sup> f known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
/TJS/	C1	5,051,257		Pietronigro	09/24/1991	
ī	C2	5,320,634		Vigil et al.	06/14/1994	
	СЗ	5,370,614		Amundson et al.	12/06/1994	
	C4	5,554,182		Dinh et al.	09/10/1996	
	C5	5,571,086		Kaplan et al.	11/05/1996	
	C6	5,626,562		Castro	05/06/1997	
	C7	5,792,158		Lary	08/11/1998	
	C8	6,039,721		Johnson et al.	03/21/2000	
	C9	6,146,358		Rowe	11/14/2000	
	C10	6,306,151	B1	Lary	10/23/2001	
	C11	6,419,692		Yang et al.	07/16/2002	
	C12	6,491,938	B2	Kunz et al.	12/10/2002	
	C13	6,544,544		Hunter et al.	04/08/2003	
	C14	6,599,928	B2	Kunz et al.	07/29/2003	
	C15	6,616,650	B1	Rowe	09/09/2003	
	C16	2002/0123505	A1	Mollison et al.	09/05/2002	
1/	C17	2003/0100600	A1	Kinsella et al.	05/29/2003	
W	C18	2005/0250672	A9	Speck et al.	11/10/2005	
/TJS/	C19	2006/0020243	A1	Speck et al.	01/26/2006	

## **FOREIGN PATENT DOCUMENTS**

	,		For	eign Patent Do	cument		Date of Publication of	Pages, Columns, Lines, Where Relevant	
	Examiner Initials*	Cite No.	Office <sup>3</sup>	Number 4	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T 6
ı	/TJS/	C20	DE	4225553	C1	Michael Rudolf	05/11/1994		

EXAMINER	/Thomas J Sweet/ (04/11/2007)	DATE	
SIGNATURE	/Thomas J Sweet/ (04/11/2007)	CONSIDERED	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the scrial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

	، بود پذر		614	~W			
			•	F. In.		Complete If Known	
	ubstitute for form	1	EE'.	Applica	on Number	10/618,977	
INFOE	MATION F	NECI O	gi me	Filines	ate	July 14, 2003	
OTAT		ADDI		CENTER N	amed Inventor	Brian Bates, et al.	
SIAII	FIMENIBA	APPLI	CARRES	Group	Yate amed Inventor Art Unit	1762	
	e as many sheets			Examir	er Name	Thomas Sweet	
Sheet	2	of 2		Attorne	y Docket Number	PA-5335-RFB (8627/742)	***

**FOREIGN PATENT DOCUMENTS** 

TJS			For	eign Patent Docume		KEIGH PATENT DOCUM		Pages, Columns, Lines,	
C22 DE 69403966			Office 3	Kind Code <sup>5</sup> Number <sup>4</sup> (if known)			Cited Document	Passages or Relevant	.Т в
C23 DE 10244847.7	7TJS/	C21	DE	4446694		Schering AG	12/1994		
C24 EP 0706376 Angiotech Pharm. Inc. 07/19/1993  C25 EP 0829238 B1 Gray Lary Banning 09/13/2000  C26 WO 92/11890 A1 Michael Dror 07/23/1992  C27 WO 92/15282 Keith March 09/17/1992  C28 WO 94/07484 Shively et al. 04/14/1994  C29 WO 94/23787 A1 David Rammler 10/27/1994  C30 WO 95/03795 Government of USA 07/29/1993  C31 WO 96/20718 A2 Charles Hart 07/11/1996  C32 WO 96/38183 Ramot Univ. Israel 05/1995  C33 WO 97/26862 Schering AG 01/1997  C34 WO 98/24427 Angiotech Pharm. Inc. 12/1996  C35 WO 98/43618 Neorxcorp. 03/1997  C36 WO 99/62510 Angiotech Pharm. Inc. 06/1998  C37 WO 0006152 Novopharm Biotech 07/1998  C38 WO 00/10552 Global Vascular 08/1998  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  V C42 WO 03/048166 Gaedicke e al. 06/12/2003	1	C22	DE	69403966		Burt et al.	02/05/1998		
C25 EP 0829238 B1 Gray Lary Banning 09/13/2000  C26 WO 92/11890 A1 Michael Dror 07/23/1992  C27 WO 92/15282 Kelth March 09/17/1992  C28 WO 94/07484 Shively et al. 04/14/1994  C29 WO 94/23787 A1 David Rammler 10/27/1994  C30 WO 95/03795 Government of USA 07/29/1993  C31 WO 96/20718 A2 Charles Hart 07/11/1996  C32 WO 96/38183 Ramot Univ. Israel 05/1995  C33 WO 97/26862 Schering AG 01/1997  C34 WO 98/24427 Angiotech Pharm. Inc. 12/1996  C35 WO 98/43618 Neorxcorp. 03/1997  C36 WO 99/62510 Angiotech Pharm. Inc. 06/1998  C37 WO 0006152 Novopharm Biotech 07/1998  C38 WO 00/10552 Global Vascular Concepts  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  V C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C23	DE	10244847.7			11/11/2002		
C26 WO 92/11890 A1 Michael Dror 07/23/1992  C27 WO 92/15282 Kelth March 09/17/1992  C28 WO 94/07484 Shively et al. 04/14/1994  C29 WO 94/23787 A1 David Rammler 10/27/1994  C30 WO 95/03795 Government of USA 07/29/1993  C31 WO 96/20718 A2 Charles Hart 07/11/1996  C32 WO 96/38183 Ramot Univ. Israel 05/1995  C33 WO 97/26862 Schering AG 01/1997  C34 WO 98/24427 Angiotech Pharm. Inc. 12/1996  C35 WO 98/43618 Neorxcorp. 03/1997  C36 WO 99/62510 Angiotech Pharm. Inc. 06/1998  C37 WO 0006152 Novopharm Biotech 07/1998  C38 WO 00/10552 Global Vascular Concepts  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  V C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C24	EΡ	0706376		Angiotech Pharm. Inc.	07/19/1993		
C27 WO 92/15282 Kelth March 09/17/1992  C28 WO 94/07484 Shively et al. 04/14/1994  C29 WO 94/23787 A1 David Rammler 10/27/1994  C30 WO 95/03795 Government of USA 07/29/1993  C31 WO 96/20718 A2 Charles Hart 07/11/1996  C32 WO 96/38183 Ramot Univ. Israel 05/1995  C33 WO 97/26862 Schering AG 01/1997  C34 WO 98/24427 Angiotech Pharm. Inc. 12/1996  C35 WO 98/43618 Neorxcorp. 03/1997  C36 WO 99/62510 Angiotech Pharm. Inc. 06/1998  C37 WO 0006152 Novopharm Biotech 07/1998  C38 WO 00/10552 Global Vascular 08/1998  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  V C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C25	EP	0829238	B1	Gray Lary Banning	09/13/2000		
C28         WO         94/07484         Shively et al.         04/14/1994           C29         WO         94/23787         A1         David Rammler         10/27/1994           C30         WO         95/03795         Government of USA         07/29/1993           C31         WO         96/20718         A2         Charles Hart         07/11/1996           C32         WO         96/38183         Ramot Univ. Israel         05/1995           C33         WO         97/26862         Schering AG         01/1997           C34         WO         98/24427         Angiotech Pharm. Inc.         12/1996           C35         WO         98/43618         Neorxcorp.         03/1997           C36         WO         99/62510         Angiotech Pharm. Inc.         06/1998           C37         WO         0006152         Novopharm Biotech         07/1998           C38         WO         00/10552         Global Vascular Concepts         08/1998           C39         WO         00/44414         A1         You-Ling Fan         08/03/2000           C40         WO         00/45744         Dachuan Yang         08/10/2000           C42         WO         03/026718		C26	wo	92/11890	A1	Michael Dror	07/23/1992		
C29 WO 94/23787 A1 David Rammler 10/27/1994  C30 WO 95/03795 Government of USA 07/29/1993  C31 WO 96/20718 A2 Charles Hart 07/11/1996  C32 WO 96/38183 Ramot Univ. Israel 05/1995  C33 WO 97/26862 Schering AG 01/1997  C34 WO 98/24427 Angiotech Pharm. Inc. 12/1996  C35 WO 98/43618 Neorxcorp. 03/1997  C36 WO 99/62510 Angiotech Pharm. Inc. 06/1998  C37 WO 0006152 Novopharm Biotech 07/1998  C38 WO 00/10552 Global Vascular 08/1998  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  V C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C27	wo	92/15282		Keith March	09/17/1992		
C30         WO         95/03795         Government of USA         07/29/1993           C31         WO         96/20718         A2         Charles Hart         07/11/1996           C32         WO         96/38183         Ramot Univ. Israel         05/1995           C33         WO         97/26862         Schering AG         01/1997           C34         WO         98/24427         Angiotech Pharm. Inc.         12/1996           C35         WO         98/43618         Neorxcorp.         03/1997           C36         WO         99/62510         Angiotech Pharm. Inc.         06/1998           C37         WO         0006152         Novopharm Biotech         07/1998           C38         WO         00/10552         Global Vascular Concepts         08/1998           C39         WO         00/44414         A1         You-Ling Fan         08/03/2000           C40         WO         00/45744         Dachuan Yang         08/10/2000           C41         WO         02/066092         Levesque et al.         08/29/2002           C42         WO         03/026718         A1         Anthony Ragheb         04/03/2003           C43         WO         03/048166		C28	wo	94/07484		Shively et al.	04/14/1994		
C31 WO 96/20718 A2 Charles Hart 07/11/1996  C32 WO 96/38183 Ramot Univ. Israel 05/1995  C33 WO 97/26862 Schering AG 01/1997  C34 WO 98/24427 Angiotech Pharm. Inc. 12/1996  C35 WO 98/43618 Neorxcorp. 03/1997  C36 WO 99/62510 Angiotech Pharm. Inc. 06/1998  C37 WO 0006152 Novopharm Biotech 07/1998  C38 WO 00/10552 Global Vascular Concepts  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C29	wo	94/23787	A1	David Rammler	10/27/1994		
C32         WO         96/38183         Ramot Univ. Israel         05/1995           C33         WO         97/26862         Schering AG         01/1997           C34         WO         98/24427         Angiotech Pharm. Inc.         12/1996           C35         WO         98/43618         Neorxcorp.         03/1997           C36         WO         99/62510         Angiotech Pharm. Inc.         06/1998           C37         WO         0006152         Novopharm Biotech         07/1998           C38         WO         00/10552         Global Vascular Concepts         08/1998           C39         WO         00/44414         A1         You-Ling Fan         08/03/2000           C40         WO         00/45744         Dachuan Yang         08/10/2000           C41         WO         02/066092         Levesque et al.         08/29/2002           C42         WO         03/026718         A1         Anthony Ragheb         04/03/2003           C43         WO         03/048166         Gaedicke e al.         06/12/2003		C30	wo	95/03795		Government of USA			
C32 WO 97/26862 Schering AG 01/1997  C34 WO 98/24427 Angiotech Pharm. Inc. 12/1996  C35 WO 98/43618 Neorxcorp. 03/1997  C36 WO 99/62510 Angiotech Pharm. Inc. 06/1998  C37 WO 0006152 Novopharm Biotech 07/1998  C38 WO 00/10552 Global Vascular Concepts  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C31	wo	96/20718	A2	Charles Hart	07/11/1996		
C34 WO 98/24427 Angiotech Pharm. Inc. 12/1996  C35 WO 98/43618 Neorxcorp. 03/1997  C36 WO 99/62510 Angiotech Pharm. Inc. 06/1998  C37 WO 0006152 Novopharm Biotech 07/1998  C38 WO 00/10552 Global Vascular Concepts  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C32	wo	96/38183		Ramot Univ. Israel	05/1995		
C35 WO 98/43618 Neorxcorp. 03/1997  C36 WO 99/62510 Angiotech Pharm. Inc. 06/1998  C37 WO 0006152 Novopharm Biotech 07/1998  C38 WO 00/10552 Global Vascular Concepts  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C33	wo	97/26862		Schering AG	01/1997		<u> </u>
C36 WO 99/62510 Angiotech Pharm. Inc. 06/1998  C37 WO 0006152 Novopharm Biotech 07/1998  C38 WO 00/10552 Global Vascular Concepts  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003	<b>—</b>	C34	wo	98/24427		Angiotech Pharm. Inc.	12/1996		
C37 WO 0006152 Novopharm Biotech 07/1998  C38 WO 00/10552 Global Vascular Concepts  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C35	wo	98/43618		Neorxcorp.	03/1997		
C38 WO 00/10552 Global Vascular Concepts 08/1998  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C36	wo	99/62510		Angiotech Pharm. Inc.	06/1998		
Concepts  C39 WO 00/44414 A1 You-Ling Fan 08/03/2000  C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C37	wo	0006152		Novopharm Biotech	07/1998		1_
C40 WO 00/45744 Dachuan Yang 08/10/2000  C41 WO 02/066092 Levesque et al. 08/29/2002  C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C38	wo	00/10552					
C41 WO 02/066092 Levesque et al. 08/29/2002  C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003  C43 WO 03/048166 Gaedicke e al. 06/12/2003		C39	wo	00/44414	A1	You-Ling Fan	08/03/2000		
C42 WO 03/026718 A1 Anthony Ragheb 04/03/2003 C43 WO 03/048166 Gaedicke e al. 06/12/2003		C40	wo	00/45744		Dachuan Yang	08/10/2000		
C43 WO 03/048166 Gaedicke e al. 06/12/2003		C41	wo	02/066092		Levesque et al.			
V C43 VC	1/	C42	wo	03/026718	A1	Anthony Ragheb			<u> </u>
/TIC/ C44 WO 2004/028610 A2 Ulrich Speck et al. 04/08/2004	V	C43	wo	03/048166		Gaedicke e al.			
1/100/ 1 2771 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	/TJS/	C44	wo	2004/028610	A2	Ulrich Speck et al.	04/08/2004		

EXAMINER		DATE CONSIDERED	
FVVIAIIIAFIX	/Thomas J Sweet/ (04/11/2007)	D/ 1/2 0011012211122	
SIGNATURE	/ 1110111a5 J SWEET (04/ 1 1/2007)		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.